Advertisement

Journal of Gastrointestinal Surgery

, Volume 23, Issue 5, pp 966–974 | Cite as

Circulating Leptin and Branched Chain Amino Acids—Correlation with Intraductal Papillary Mucinous Neoplasm Dysplastic Grade

  • Michele T. Yip-Schneider
  • Rachel Simpson
  • Rosalie A. Carr
  • Huangbing Wu
  • Hao Fan
  • Ziyue Liu
  • Murray Korc
  • Jianjun ZhangEmail author
  • C. Max SchmidtEmail author
Original Article
  • 92 Downloads

Abstract

Background

The most common type of mucinous pancreatic cyst that may progress to pancreatic cancer is intraductal papillary mucinous neoplasm (IPMN). Low-risk IPMN with low-/moderate-grade dysplasia may be safely watched, whereas high-risk IPMN with high-grade dysplasia or invasive components should undergo resection. However, there is currently no reliable means of making this distinction. We hypothesize that blood concentrations of insulin resistance biomarkers may aid in the differentiation of low- and high-risk IPMN.

Methods

Plasma/serum was collected from consented patients undergoing pancreatic resection. IPMN diagnosis and dysplastic grade were confirmed by surgical pathology. The study included 235 IPMN (166 low/moderate grade, 39 high grade, 30 invasive). Circulating levels of leptin, branched chain amino acids (BCAA), and retinol-binding protein-4 (RBP-4) were measured by enzyme-linked immunoassay and correlated with surgical pathology.

Results

Circulating leptin levels (mean ± SE) were significantly higher in patients with low/moderate IPMN than in high-grade/invasive IPMN (15,803 ± 1686 vs. 10,275 ± 1228 pg/ml; p = 0.0086). Leptin levels were positively correlated with BMI (r = 0.65, p < 0.0001) and were higher in females (p < 0.0001). Stratified analysis showed that mean leptin levels were significantly different between low/moderate and high/invasive IPMNs only in females (24,383 ± 2748 vs. 16,295 ± 2040 pg/ml; p = 0.020). Conversely, circulating BCAA levels were lower in low/moderate IPMN than in high-grade/invasive IPMN (0.38 ± 0.007 vs. 0.42 ± 0.01 mM; p = 0.011). No significant differences in RBP-4 levels were observed.

Conclusions

Circulating leptin in females and BCAA correlates with IPMN dysplastic grade and, if combined with clinical characteristics, have the potential to improve clinical decision-making.

Keywords

Leptin BCAA IPMN Biomarker Pancreatic cyst 

Abbreviations

IPMN

Intraductal papillary mucinous neoplasm

BCAA

Branched chain amino acids

RBP-4

Retinol-binding protein-4

ELISA

Enzyme-linked immunosorbent assay

PDAC

Pancreatic ductal adenocarcinoma

Notes

Support

This study was supported by the National Institutes of Health Grant #1R21CA209366-01, Indiana Clinical and Translational Sciences Institute funded in part by Grant #UL1TR001108 from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award, and National Center for Research Resources Construction Grant #RR020128.

Author Contributions

Yip-Schneider, Zhang, and Schmidt significantly contributed to the conception/design/data interpretation, drafting/revision of the work, as well as approve of the final version and agree to be accountable for all aspects of the work.

Liu and Korc significantly contributed to data interpretation and revision of the work as well as approve of the final version and agree to be accountable for all aspects of the work.

Simpson, Carr, Wu, and Hao significantly contributed to data acquisition/analysis, revision of the work, as well as approval of the final version and agree to be accountable for all aspects of the work.

Compliance with Ethical Standards

All patients and healthy controls provided informed consent in accordance with the Indiana University Institutional Review Board.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    American Cancer Society. Cancer Facts & Figures 2018. Atlanta: American Cancer Society; 2018. Available at: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2018.html. Accessed March 20, 2018.Google Scholar
  2. 2.
    Harinck F, Poley JW, Kluijt I, Fockens P, Bruno MJ. Is early diagnosis of pancreatic cancer fiction? Surveillance of individuals at high risk for pancreatic cancer. Dig Dis 2010;28:670–678.CrossRefGoogle Scholar
  3. 3.
    Pitman MB, Lewandrowski K, Shen J, Sahani D, Brugge W, Fernandez-del Castillo C. Pancreatic cysts: preoperative diagnosis and clinical management. Cancer Cytopathol 2010;118:1–13.CrossRefGoogle Scholar
  4. 4.
    Sheehan MK, Beck K, Pickleman J, Aranha GV. Spectrum of cystic neoplasms of the pancreas and their surgical management. Arch Surg 2003;138:657–660; discussion 660-652.CrossRefGoogle Scholar
  5. 5.
    Tanaka M, Fernandez-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, Kimura W, Levy P, Pitman MB, Schmidt CM, Shimizu M, Wolfgang CL, Yamaguchi K, Yamao K. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012;12:183–197.CrossRefGoogle Scholar
  6. 6.
    Tang RS, Weinberg B, Dawson DW, Reber H, Hines OJ, Tomlinson JS, Chaudhari V, Raman S, Farrell JJ. Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol 2008;6:815–819; quiz 719.CrossRefGoogle Scholar
  7. 7.
    Jang JY, Park T, Lee S, Kang MJ, Lee SY, Lee KB, Chang YR, Kim SW. Validation of international consensus guidelines for the resection of branch duct-type intraductal papillary mucinous neoplasms. Br J Surg 2014;101:686–692.CrossRefGoogle Scholar
  8. 8.
    Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, Ventura V, Foti D, Chiefari E, Brunetti A. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res 2012;2012:789174.Google Scholar
  9. 9.
    Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, Albanes D. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005;294:2872–2878.CrossRefGoogle Scholar
  10. 10.
    Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001;286:921–929.CrossRefGoogle Scholar
  11. 11.
    Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005;92:2076–2083.CrossRefGoogle Scholar
  12. 12.
    Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005;293:194–202.CrossRefGoogle Scholar
  13. 13.
    Nowak C, Sundstrom J, Gustafsson S, Giedraitis V, Lind L, Ingelsson E, Fall T. Protein Biomarkers for Insulin Resistance and Type 2 Diabetes Risk in Two Large Community Cohorts. Diabetes 2016;65:276–284.Google Scholar
  14. 14.
    Paz-Filho G, Mastronardi C, Wong ML, Licinio J. Leptin therapy, insulin sensitivity, and glucose homeostasis. Indian J Endocrinol Metab 2012;16:S549–555.CrossRefGoogle Scholar
  15. 15.
    Yoon MS. The Emerging Role of Branched-Chain Amino Acids in Insulin Resistance and Metabolism. Nutrients 2016;8(7): 405.  https://doi.org/10.3390/nu8070405..CrossRefGoogle Scholar
  16. 16.
    Zhao X, Han Q, Liu Y, Sun C, Gang X, Wang G. The Relationship between Branched-Chain Amino Acid Related Metabolomic Signature and Insulin Resistance: A Systematic Review. Journal Diabetes Res 2016;2016:2794591.Google Scholar
  17. 17.
    Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356–362.CrossRefGoogle Scholar
  18. 18.
    Korc M. Update on diabetes mellitus. Dis Markers 2004;20:161–165.CrossRefGoogle Scholar
  19. 19.
    Fisher WE, Boros LG, Schirmer WJ. Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors. J Surg Res 1996;63:310–313.CrossRefGoogle Scholar
  20. 20.
    Krechler T, Zeman M, Vecka M, Macasek J, Jachymova M, Zima T, Zak A. Leptin and adiponectin in pancreatic cancer: connection with diabetes mellitus. Neoplasma 2011;58:58–64.CrossRefGoogle Scholar
  21. 21.
    Gasiorowska A, Talar-Wojnarowska R, Kaczka A, Borkowska A, Czupryniak L, Malecka-Panas E. Role of adipocytokines and its correlation with endocrine pancreatic function in patients with pancreatic cancer. Pancreatology 2013;13:409–414.CrossRefGoogle Scholar
  22. 22.
    Mondello P, Lacquaniti A, Mondello S, Bolignano D, Pitini V, Aloisi C, Buemi M. Emerging markers of cachexia predict survival in cancer patients. BMC Cancer 2014;14:828.CrossRefGoogle Scholar
  23. 23.
    Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, Yuan C, Bao Y, Townsend MK, Tworoger SS, Davidson SM, Papagiannakopoulos T, Yang A, Dayton TL, Ogino S, Stampfer MJ, Giovannucci EL, Qian ZR, Rubinson DA, Ma J, Sesso HD, Gaziano JM, Cochrane BB, Liu S, Wactawski-Wende J, Manson JE, Pollak MN, Kimmelman AC, Souza A, Pierce K, Wang TJ, Gerszten RE, Fuchs CS, Heiden MGV, Wolpin BM. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med 2014;20:1193–1198.CrossRefGoogle Scholar
  24. 24.
    Schmidt CM, Yip-Schneider MT, Ralstin MC, Wentz S, DeWitt J, Sherman S, Howard TJ, McHenry L, Dutkevitch S, Goggins M, Nakeeb A, Lillemoe KD. PGE(2) in pancreatic cyst fluid helps differentiate IPMN from MCN and predict IPMN dysplasia. J Gastrointest Surg 2008;12:243–249.CrossRefGoogle Scholar
  25. 25.
    Yip-Schneider MT, Carr RA, Wu H, Schmidt CM. Prostaglandin E2: A Pancreatic Fluid Biomarker of Intraductal Papillary Mucinous Neoplasm Dysplasia. J Am Coll Surg 2017;225:481–487.CrossRefGoogle Scholar
  26. 26.
    Moris D, Damaskos C, Spartalis E, Papalampros A, Vernadakis S, Dimitroulis D, Griniatsos J, Felekouras E, Nikiteas N. Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas. Anticancer Res 2017;37:2185–2194.CrossRefGoogle Scholar
  27. 27.
    Permuth-Wey J, Chen DT, Fulp WJ, Yoder SJ, Zhang Y, Georgeades C, Husain K, Centeno BA, Magliocco AM, Coppola D, Malafa M. Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas. Cancer Prev Res (Phila) 2015;8:826–834.CrossRefGoogle Scholar
  28. 28.
    Maker AV, Katabi N, Gonen M, DeMatteo RP, D'Angelica MI, Fong Y, Jarnagin WR, Brennan MF, Allen PJ. Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg Oncol 2011;18:199–206.CrossRefGoogle Scholar
  29. 29.
    Wang W, Zhang L, Chen L, Wei J, Sun Q, Xie Q, Zhou X, Zhou D, Huang P, Yang Q, Xie H, Zhou L, Zheng S. Serum carcinoembryonic antigen and carbohydrate antigen 19-9 for prediction of malignancy and invasiveness in intraductal papillary mucinous neoplasms of the pancreas: A meta-analysis. Biomed Rep 2015;3:43–50.CrossRefGoogle Scholar
  30. 30.
    Roch AM, Ceppa EP, Al-Haddad MA, DeWitt JM, House MG, Zyromski NJ, Nakeeb A, Schmidt CM. The natural history of main duct-involved, mixed-type intraductal papillary mucinous neoplasm: parameters predictive of progression. Ann Surg 2014;260:680–688; discussion 688-690.CrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2018

Authors and Affiliations

  • Michele T. Yip-Schneider
    • 1
    • 2
    • 3
    • 4
  • Rachel Simpson
    • 1
    • 4
  • Rosalie A. Carr
    • 1
    • 4
  • Huangbing Wu
    • 1
    • 4
  • Hao Fan
    • 5
  • Ziyue Liu
    • 6
    • 7
  • Murray Korc
    • 3
    • 8
    • 9
  • Jianjun Zhang
    • 3
    • 5
    Email author
  • C. Max Schmidt
    • 1
    • 2
    • 3
    • 4
    • 8
    Email author
  1. 1.Department of SurgeryIndiana University School of MedicineIndianapolisUSA
  2. 2.Walther Oncology CenterIndianapolisUSA
  3. 3.Indiana University Simon Cancer CenterIndianapolisUSA
  4. 4.Indiana University Health Pancreatic Cyst and Cancer Early Detection CenterIndianapolisUSA
  5. 5.Department of EpidemiologyIndiana University Richard M. Fairbanks School of Public HealthIndianapolisUSA
  6. 6.Department of BiostatisticsIndiana University School of MedicineIndianapolisUSA
  7. 7.Department of BiostatisticsIndiana University Richard M. Fairbanks School of Public HealthIndianapolisUSA
  8. 8.Department of Biochemistry/Molecular BiologyIndiana University School of MedicineIndianapolisUSA
  9. 9.Department of MedicineIndiana University School of MedicineIndianapolisUSA

Personalised recommendations